Peptides
BPC-157 + TB-500
10+10mg
BPC-157 and TB-500 research blend, 10+10mg vial.
Content-verified · Third-party tested · Batch UKPL-9514 · View certificate
- Same-day dispatch before 3pm, Mon to Fri
- Add £14.01 more for free UK delivery
- Cold-chain shipping. Always. Dry-cold pack, Royal Mail Tracked 24
- Lost, damaged or wrong? Replaced free if you tell us within 48 hours.
- Research use only. For in-vitro laboratory research. Not for use in humans or animals, or in food, drugs or diagnostics. Not evaluated by the MHRA or FDA. The buyer is responsible for handling and regulatory compliance.
Bulk Pricing
Counted across your basket, any mix of products.
| Vials in basket | Discount | Per vial |
|---|---|---|
| 1 | None | £54.99 |
| 3-4 | 5% | £52.24save £2.75 |
| 5-9 | 8% | £50.59save £4.40 |
| 10-50 | 12% | £48.39save £6.60 |
Bacteriostatic Water 10ml
Required to reconstitute lyophilised peptides.
What is BPC-157 + TB-500?
BPC-157 + TB-500 10+10mg is the larger pre-blended vial: 10mg of each peptide, 20mg in total, as lyophilised powder under batch UKPL-9514. The chemistry and the mass ratio match the 5+5mg vial.
Full description
BPC-157 is the 15-residue peptide GEPPPGKPADDAGLV at 1419.53 g/mol. TB-500 is listed with the identifiers of thymosin beta 4: CAS 77591-33-4 and 4963.4 g/mol. Their mechanisms and literature are covered on the single BPC-157 and TB-500 pages. Doubling both masses leaves the molar ratio unchanged. No controlled study has tested this combination.
BPC-157 + TB-500 Research Applications
- BPC-157: VEGFR2 upregulation in endothelial cells (Hsieh et al., 2017) and more FAK and paxillin phosphorylation in tendon fibroblasts (Chang et al., 2011).
- Thymosin beta 4: integrin-linked kinase and Akt activation in mouse cardiac models (Bock-Marquette et al., Nature, 2004). Its seven-residue actin-binding sequence, LKKTETQ, promoted dermal repair in diabetic and aged mice (Philp et al., 2003).
- Human evidence: only three pilot studies of BPC-157 and no large-scale trials (McGuire et al., Curr Rev Musculoskelet Med, 2025).
Study details
The 10+10mg vial suits preclinical soft-tissue and cell-migration designs that use more peptide than a 5+5mg vial supplies. Examples are long explant or co-culture experiments, concentration-response matrices, and studies that must hold one batch across every arm.
10+10mg vs 5+5mg: What the Rung Changes
Nothing chemical changes between the two sizes. Both are equal by mass and about 3.5 to 1 by moles in favour of BPC-157. What changes is procedure. The 10+10mg vial gives twice the peptide per reconstitution, so a study needing a given total mass uses half the vials and crosses one batch boundary instead of two. It supports double the concentration at a fixed fill volume, or double the volume at a fixed concentration. The cost is that 20mg shares one in-use window, which wastes material in slow, low-throughput designs.
Research Overview
BPC-157 + TB-500 10+10mg is a co-formulated research vial holding 10mg of each peptide, 20mg of total peptide, supplied as lyophilised powder. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, molecular weight 1419.53 g/mol. TB-500 is the synthetic 17-23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, CAS 77591-33-4, molecular weight 4963.4 g/mol. Both compounds sit among the most referenced peptides in cell migration, angiogenesis and tissue repair research, and their individual literatures are covered in full on the separate BPC-157 and TB-500 product pages.
The two components report through distinct mechanisms. For BPC-157, Hsieh and colleagues (J Mol Med, 2017) reported upregulation and internalisation of VEGFR2 in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reported increased phosphorylation of focal adhesion kinase and paxillin in cultured rat tendon fibroblasts. For thymosin beta-4, Bock-Marquette and colleagues (Nature, 2004) reported cell migration and survival effects in mouse cardiac injury models, and Philp and colleagues (Wound Repair Regen, 2003) found the synthetic actin-binding domain peptide LKKTETQ promoted dermal wound repair in diabetic and aged mice.
This is the higher-mass presentation of the blend also offered at 5+5mg, and the chemistry is identical; what changes is quantity. Doubling the mass doubles the molar amounts without altering the ratio: 10mg of BPC-157 is roughly 7.0 µmol and 10mg of TB-500 roughly 2.0 µmol, an approximate 3.5 to 1 molar ratio in favour of BPC-157, exactly as in the 5+5mg rung. The 10+10mg vial means fewer vials, fewer reconstitution events and fewer lot boundaries for a given total mass, at the cost of placing 20mg behind a single in-use window.
No controlled study has evaluated this specific combination, so combination-specific claims cannot be supported, and a 2025 review by McGuire and colleagues (Curr Rev Musculoskelet Med) found no adequately powered randomised controlled trials for BPC-157 in musculoskeletal healing. It is not a licensed medicine and is not for human consumption.
Product Specifications
- CAS Number
- 137525-51-0 / 77591-33-4
- Molecular Weight
- 1419.53 / 4963.4 g/mol
- BPC-157 Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- TB-500
- Thymosin beta 4, N-acetylated, 43 residues (per listed CAS and molecular weight)
- Molar Ratio
- About 3.5 : 1 BPC-157 to TB-500 (equal mass, not equimolar)
- Batch
- UKPL-9514
- Storage
- -20°C lyophilised, 2-8°C reconstituted
- Appearance
- White lyophilised powder
- Form
- Lyophilised powder
Certificate of Analysis
Third-party tested
- Batch
- UKPL-9514
- Purity
- Content-verified
- Method
- RP-HPLC
- Lab
- Janoshik Analytical
- Tested
- Oct 2026
Original Janoshik report. Tap to enlarge.Need the certificate for an earlier batch? Request an older CoA
Storage and Reconstitution
Keep sealed vials at -20°C, away from light and moisture. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks, or freeze single-use aliquots at -20°C. With 20mg behind one reconstitution date, aliquot early and avoid repeated freeze-thaw cycles.
Vials are sold on their own, without bacteriostatic water for mixing or other supplies.
How to reconstitute and handle
Treat the vial as one 20mg preparation, with the fill volume set by the concentration your protocol needs. Let the vial and the bacteriostatic water reach room temperature and swab both stoppers. Add the water slowly down the inside wall and swirl gently. Do not shake or vortex. The larger cake can take a little longer to dissolve, so wait for a fully clear, colourless solution. The peptides cannot be separated afterwards. Label the vial with fill volume, concentration and date.
- The two components cannot be separated after reconstitution, and the shorter of the two in-use windows governs the whole preparation. Express the preparation in molar terms only if the 3.5 to 1 asymmetry is accounted for.
- Handle under aseptic laboratory conditions with sterile equipment, prepare single-use aliquots for longer storage, and avoid repeated freeze-thaw cycles.
For the full method, see the peptide reconstitution guide and the reconstitution calculator.
Research References
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al., J Appl Physiol, 2011)
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice (Philp et al., Wound Repair Regen, 2003)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., Curr Rev Musculoskelet Med, 2025)
Published research on BPC-157 + TB-500 is indexed on PubMed. See our full UK buyer's guide for Wolverine Stack and UK buyer's guide for BPC-157 + TB-500 10+10mg.
BPC-157 + TB-500 Price (UK)
BPC-157 + TB-500 is for sale in 2 vial sizes, priced from £29.99 for 5+5mg to £54.99 for 10+10mg. Every size ships from our UK facility, each with its own batch certificate. UK delivery is £4.50 by Royal Mail Tracked 24, free over £69.
| Vial | Price | Cost per mg | Availability |
|---|---|---|---|
| BPC-157 + TB-500 5+5mg | £29.99 | £3.00 | In stock |
| BPC-157 + TB-500 10+10mgThis page | £54.99 | £2.75Best value | In stock |
Prices are in GBP per vial and match the basket. See the FAQ for delivery and payment options, and quality & testing for how each batch is checked.
Frequently Asked Questions
What is the difference between the 10+10mg and 5+5mg vials?
The chemistry is identical and the mass is doubled. Both vials hold equal masses of the two peptides, both carry the same approximate 3.5 to 1 molar ratio in favour of BPC-157, and both are supplied as lyophilised powder. The 10+10mg vial holds 20mg of total peptide behind a single reconstitution date, so a given experiment uses half the vials, while the 5+5mg rung spreads the same mass across two staggered in-use windows.
Is the blend equimolar?
No. It is equal by mass and roughly 3.5 to 1 by moles in favour of BPC-157, because the molecular weights are 1419.53 g/mol for BPC-157 and 4963.4 g/mol for TB-500. Ten milligrams of each component corresponds to approximately 7.0 µmol and 2.0 µmol respectively. Mass-based and mole-based descriptions of this vial are not interchangeable.
Is there clinical evidence for using BPC-157 and TB-500 together?
No controlled study has evaluated this specific combination, so combination-specific claims cannot be supported. Each compound has its own substantial preclinical literature, and a 2025 review by McGuire and colleagues (Curr Rev Musculoskelet Med) identified only three human pilot studies for BPC-157 with no adequately powered randomised controlled trials. The blend is supplied as a convenience of format for combined-protocol research, not on the basis of demonstrated combination synergy.
Is the 10+10mg blend equimolar?
No. By moles it is about 3.5 to 1 in favour of BPC-157, the same as the 5+5mg vial. The 10+10mg vial holds about 7.0 µmol of BPC-157 and 2.0 µmol of TB-500.
Is there evidence for using BPC-157 and TB-500 together?
Not for the pair itself. No controlled study has compared the combination with either peptide alone. The blend is supplied for convenience in combined preclinical designs, not because a combined effect has been shown.
Where can I buy a BPC-157 and TB-500 10+10mg blend in the UK?
UK Peptide Lab sells the 10+10mg blend from UK stock, batch UKPL-9514, with a Janoshik Analytical certificate published on the product page: BPC-157 11.84mg and TB-500 11.33mg per vial, quantified on 26 October 2026. Orders placed before 3pm UK time on a working day are dispatched the same day, and UK Royal Mail Tracked delivery is free over £69.
Related Products
